journal
https://read.qxmd.com/read/38863260/global-and-regional-burden-of-vaccine-induced-thrombotic-thrombocytopenia-1969-2023-comprehensive-findings-with-critical-analysis-of-the-international-pharmacovigilance-database
#1
JOURNAL ARTICLE
Sooji Lee, Hyesu Jo, Selin Woo, Yi Deun Jeong, Hayeon Lee, Kyeongmin Lee, Jinseok Lee, Hyeon Jin Kim, Jiseung Kang, Louis Jacob, Lee Smith, Masoud Rahmati, Guillermo F López Sánchez, Elena Dragioti, Yejun Son, Soeun Kim, Seung Geun Yeo, Jaeyu Park, Dong Keon Yon
OBJECTIVE: The scarcity of studies on vaccine-induced thrombosis and thrombocytopenia syndrome (TTS) limits the comprehensive understanding of vaccine safety on a global scale. Therefore, the objective of this study is to assess the global burden of vaccine-induced TTS, identify the vaccines most associated with it, and suggest clinical implications regarding vaccination. METHODS: This study employed the World Health Organization international pharmacovigilance database, extracting records of vaccine-induced immune thrombotic thrombocytopenia from 1969 to 2023 (total reports, n > 130 million)...
June 11, 2024: European Journal of Haematology
https://read.qxmd.com/read/38853698/time-dependent-cost-comparison-and-health-economic-impact-analysis-of-second-line-interventions-for-transplant-ineligible-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma
#2
JOURNAL ARTICLE
Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs, Tabea Poos, Julia von Tresckow, Bastian von Tresckow, Hans Christian Reinhardt, Florian Kron
OBJECTIVES: Novel interventions (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tafasitamab-lenalidomide [Tafa-L], polatuzumab-rituximab-bendamustine [pola-BR]) improve clinical outcomes in second-line (2 L) treatment of transplant-ineligible patients with early relapse or refractory (R/R) diffuse large B cell lymphoma (DLBCL). The costs vary depending on the respective treatment regimen and the treatment duration, difficult comparability in reimbursement decisions...
June 10, 2024: European Journal of Haematology
https://read.qxmd.com/read/38853593/the-expression-of-galectin-9-correlates-with-mtor-and-ampk-in-murine-colony-forming-erythroid-progenitors
#3
JOURNAL ARTICLE
Tetsuo Tsukamoto
OBJECTIVES: Galectin-9 (Gal-9) is an immune checkpoint ligand for T-cell immunoglobulin and mucin domain 3. Although the roles of Gal-9 in regulating immune responses have been well investigated, their biological roles have yet to be fully documented. This study aimed to analyse the expression of Gal-9 bone marrow (BM) cells in C57BL/6J (B6) mice. Furthermore, the co-expression of Gal-9 with the mammalian target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) was investigated...
June 10, 2024: European Journal of Haematology
https://read.qxmd.com/read/38847134/prognosis-of-pediatric-bcp-all-with-ikzf1-deletions-and-impact-of-intensive-chemotherapy-results-of-scclg-2016-study
#4
JOURNAL ARTICLE
Shaofen Lin, Ning Liao, Xinyu Li, Lihua Yang, Yun-Yan He, Yan-Lai Tang, Wu-Qing Wan, Wenguang Jia, Ya-Jie Zhang, Qian Kong, Xingjiang Long, Xiang Lan, Ya-Yun Ling, Danna Lin, Xiao-Li Zhang, Chuan Wen, Chi-Kong Li, Hong-Gui Xu
BACKGROUND: IKZF1 deletion (IKZF1del ) is associated with poor prognosis in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). But the prognosis of IKZF1del combined with other prognostic stratification factors remains unclear. Whether intensified treatment improves BCP-ALL prognosis has not been determined. METHODS: A retrospective analysis was performed on 1291 pediatric patients diagnosed with BCP-ALL and treated with the South China Children's Leukemia 2016 protocol...
June 7, 2024: European Journal of Haematology
https://read.qxmd.com/read/38831675/reviewing-the-impact-of-hydroxyurea-on-dna-methylation-and-its-potential-clinical-implications-in-sickle-cell-disease
#5
REVIEW
Jasmine Lewis, Gregory M T Guilcher, Steven C Greenway
Hydroxyurea (HU) is the most common drug therapy for sickle cell disease (SCD). The clinical benefits of HU derive from its upregulation of fetal hemoglobin (HbF), which reduces aggregation of the mutated sickle hemoglobin protein (HbS) and reduces SCD symptoms and complications. However, some individuals do not respond to HU, or stop responding over time. Unfortunately, current understanding of the mechanism of action of HU is limited, hindering the ability of clinicians to identify those patients who will respond to HU and to optimize treatment for those receiving HU...
June 3, 2024: European Journal of Haematology
https://read.qxmd.com/read/38804098/differences-in-the-proteome-within-extracellular-vesicles-between-premalignant-and-malignant-plasma-cell-disorders
#6
JOURNAL ARTICLE
Patrick M Vanderboom, Yogesh Chawla, Surendra Dasari, Isha Kapoor, Shaji K Kumar, K Sreekumaran Nair, Wilson I Gonsalves
BACKGROUND: Precursor plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) always precede the development of active malignancies such as multiple myeloma (MM). There is a need for novel biomarkers to identify those patients with such precursor plasma cell disorders who rapidly progress to MM. Plasma-derived extracellular vesicles (EVs) may serve as a reservoir of potential biomarkers that can shed light on the pathogenesis and disease biology of MM. METHODS: This study isolated small EVs (SEVs) and large EVs (LEVs) from the platelet-poor peripheral blood plasma of MGUS (n = 9) and MM (n = 12) patients using the size exclusion chromatography-based method and evaluated their proteome using a label-free proteomics workflow...
May 28, 2024: European Journal of Haematology
https://read.qxmd.com/read/38785334/pharmacokinetics-pharmacodynamics-and-tolerability-of-an-aqueous-formulation-of-rusfertide-ptg-300-a-hepcidin-mimetic-in-healthy-volunteers-a-double-blind-first-in-human-study
#7
JOURNAL ARTICLE
Nishit B Modi, Richard Shames, Jason D Lickliter, Suneel Gupta
OBJECTIVES: Rusfertide is a potent peptide mimetic of hepcidin being investigated for the treatment of polycythemia vera. This randomized, placebo-controlled, double-blind study evaluated the safety, pharmacokinetics, and pharmacodynamics of single and repeated subcutaneous doses of an aqueous formulation of rusfertide in healthy adult males. METHODS: Subjects received single doses of 1, 3, 10, 20, 40, or 80 mg rusfertide or placebo. A separate cohort of subjects received two doses of 40 mg rusfertide or placebo 1 week apart...
May 24, 2024: European Journal of Haematology
https://read.qxmd.com/read/38780264/rapid-response-system-for-critically-ill-patients-with-haematological-malignancies-a-pre-and-post-intervention-study
#8
JOURNAL ARTICLE
N Mauz, M Bouisse, J Y Cahn, E Kaphan, A-S Truche, A Thiebaut-Bertrand, M Carré, C-E Bulabois, R Hamidfar-Roy, C Schwebel, S Park, J Labarere, N Terzi
BACKGROUND: This study aimed to determine whether implementing a rapid response system (RRS) is associated with improved short-term outcomes in critically ill patients with haematological malignancies. METHODS: Our monocentric pre- versus post-intervention study was conducted between January 2012 and April 2020. RRS was activated at early signs of haemodynamic or respiratory failure. The primary outcome was the reduction in Sequential Organ Failure Assessment (SOFA) score on Day 3 after intensive care unit (ICU) admission...
May 23, 2024: European Journal of Haematology
https://read.qxmd.com/read/38775787/global-prevalence-of-anemia-among-women-of-reproductive-age-2000-2019
#9
Emma P DeLoughery
A common disease with significant impacts on health and quality of life, anemia is particularly prevalent in women of reproductive age due to blood losses during menstruation and pregnancy. Data from the World Health Organization (WHO) was analyzed to compare trends in prevalence of anemia in women aged 15-49 among countries and over time with the goal of identifying regions both successful and in need of assistance in combatting anemia. Worldwide from 2000 to 2013 the prevalence of anemia among women aged 15-49 decreased, and then increased from 2013 to 2019; severe anemia decreased throughout the world from 2000 to 2019...
May 22, 2024: European Journal of Haematology
https://read.qxmd.com/read/38757452/serum-ferritin-and-risk-of-colonic-neoplasia-implications-for-the-workup-and-treatment-of-iron-deficiency
#10
REVIEW
Adam L Urback, Kylee Martens, Hannah Stowe McMurry, Anil Sharma, Caitlin Citti, Thomas G DeLoughery, Joseph J Shatzel
Iron deficiency is the most common extraintestinal sign of colonic neoplasia, including colorectal cancer (CRC) and other lower gastrointestinal pathology. Both upper endoscopy and colonoscopy is usually recommended in the work-up of patients with unexplained iron deficiency, particularly in men and postmenopausal women. As the incidence of early-onset CRC (age <50 years) rises in the United States, there is an increasing need to identify risk predictors to aid in the early detection of CRC. It remains unknown if serum ferritin (SF), and what specific threshold, can be used as a marker to stratify those at risk for CRC and other lower gastrointestinal pathology...
May 16, 2024: European Journal of Haematology
https://read.qxmd.com/read/38742655/soluble-mic-a-ipi-and-response-to-treatment-strongly-predict-survival-in-patients-with-germinal-center-diffuse-large-b-cell-lymphoma
#11
JOURNAL ARTICLE
Jorge Vela-Ojeda, Ana Cristina Olivas-Bejarano, Laura Arcelia Montiel-Cervantes, Erika Rosales-Cruz, Socrates Garcia-Gutierrez, Ruth Angelica Lezama-Palacios, Elba Reyes-Maldonado
UNLABELLED: Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma. MIC-A and MIC-B are the natural ligands for NKG2D, a receptor expressed in NK cells. MIC-A soluble isoforms (sMICA) have been described in different malignancies. OBJECTIVES: To analyze lymphocyte subsets and sMIC-A in germinal center DLBCL. MATERIALS AND METHODS: sMICA, sMICB, and peripheral blood lymphocyte subsets (CD4+, CD8+, NK, NKT, γδ T cells, and dendritic cells) were analyzed in 59 patients and 60 healthy donors...
May 14, 2024: European Journal of Haematology
https://read.qxmd.com/read/38722078/effectiveness-and-safety-of-belantamab-mafodotin-in-patients-with-relapsed-or-refractory-multiple-myeloma-in-real-world-setting-the-alfa-study
#12
JOURNAL ARTICLE
Murielle Roussel, Nathalie Texier, Virginie Nael, Jacopo Bitetti, Prani Paka, Naima Kerbouche, Lynda Sail, Xavier Colin, Xavier Leleu
OBJECTIVES: The aim of this noninterventional, retrospective ALFA study was to describe belantamab mafodotin effectiveness and safety in patients with relapsed/refractory multiple myeloma in a real-world setting in France. METHODS: Response rate, progression-free survival (PFS), overall survival (OS), and safety were assessed. RESULTS: Among the 184 patients initiating belantamab mafodotin treatment, the overall response rate was 32.7% (≥very good partial response [VGPR] 20...
May 9, 2024: European Journal of Haematology
https://read.qxmd.com/read/38717071/exercise-in-newly-diagnosed-patients-with-multiple-myeloma-a-randomized-controlled-trial-of-effects-on-physical-function-physical-activity-lean-body-mass-bone-mineral-density-pain-and-quality-of-life
#13
JOURNAL ARTICLE
Rikke F Larsen, Mary Jarden, Lisbeth R Minet, Ulf Christian Frølund, Anne Pernille Hermann, Leif Breum, Sören Möller, Niels Abildgaard
Reduced physical function caused by bone destruction, pain, anemia, infections, and weight loss is common in multiple myeloma (MM). Myeloma bone disease challenges physical exercise. Knowledge on the effects and safety of physical exercise in newly diagnosed patients with MM is limited. In a randomized, controlled trial, we studied the effect of a 10-week individualized physical exercise program on physical function, physical activity, lean body mass (LBM), bone mineral density (BMD), quality of life (QoL), and pain in patients newly diagnosed with MM...
May 8, 2024: European Journal of Haematology
https://read.qxmd.com/read/38712850/isatuximab-plus-pomalidomide-and-dexamethasone-in-patients-with-relapsed-refractory-multiple-myeloma-in-real-world-the-retrospective-image-study
#14
JOURNAL ARTICLE
Olivier Decaux, Jean Fontan, Aurore Perrot, Lionel Karlin, Cyrille Touzeau, Samantha Schulmann, Salomon Manier, Karim Belhadj, Adrien Trebouet, Patricia Zunic, Jean-Marc Schiano De Colella, Brice Castel, Zoé Van De Wyngaert, Gian Matteo Pica, Mourad Tiab, Frédérique Kuhnowski, Malek Bouketouche, Sophia Rigaudeau, Riad Benramdane, Christina Tekle, Radhia Lafore, Marianne Gaucher, Jill Corre, Xavier Leleu
BACKGROUND: IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa-Pd). METHODS: Patients aged ≥18 years with RRMM who received ≥1 dose of Isa under the EAPs between July 29, 2019 and August 30, 2020 were included. Effectiveness endpoints included progression-free survival (PFS) and response rates...
May 7, 2024: European Journal of Haematology
https://read.qxmd.com/read/38711359/a-prospective-study-of-posttransplant-cyclophosphamide-for-unrelated-donor-peripheral-blood-stem-cell-transplant-with-special-attention-to-graft-content-and-the-impact-of-a-higher-%C3%AE-%C3%AE-t-cell-dose
#15
JOURNAL ARTICLE
Chetan Jeurkar, Benjamin Leiby, Shaik Rashid, Usama Gergis, Dolores Grossso, Matthew Carabasi, Joanne Filicko-O'Hara, William O'Hara, Thomas Klumpp, Pierluigi Porcu, Neal Flomenberg, John L Wagner
Posttransplant cyclophosphamide (PtCy) has been shown to decrease post-hematopoietic stem cell transplant acute and chronic graft-versus-host disease (GVHD). In this study, PtCy was used in 44 patients along with mycophenolate and tacrolimus with HLA matched (29) and mismatched (15) unrelated donors to determine the impact of graft content on outcome; thus, all patients had flow cytometric analysis of their graft content including the number of B cells, NK cells, and various T cell subsets. Higher γδ T cell dose was associated with the development of acute GVHD (p = ...
May 6, 2024: European Journal of Haematology
https://read.qxmd.com/read/38698678/cross-talk-between-leukemic-and-immune-cells-at-the-tumor-microenvironment-in-chronic-lymphocytic-leukemia-an-update-review
#16
REVIEW
Saeid Taghiloo, Hossein Asgarian-Omran
Chronic lymphocytic leukemia (CLL) is a mature-type B cell malignancy correlated with significant changes and defects in both the innate and adaptive arms of the immune system, together with a high dependency on the tumor microenvironment. Overall, the tumor microenvironment (TME) in CLL provides a supportive niche for leukemic cells to grow and survive, and interactions between CLL cells and the TME can contribute to disease progression and treatment resistance. Therefore, the increasing knowledge of the complicated interaction between immune cells and tumor cells, which is responsible for immune evasion and cancer progression, has provided an opportunity for the development of new therapeutic approaches...
May 2, 2024: European Journal of Haematology
https://read.qxmd.com/read/38693677/fludarabine-cyclophosphamide-and-rituximab-as-first-line-treatment-in-patients-with-chronic-lymphocytic-leukemia-a-long-term-analysis-of-the-german-cll-study-group-gcllsg-registry
#17
JOURNAL ARTICLE
Nadine Kutsch, Adam Giza, Sandra Robrecht, Janina Stumpf, Anno Federhen, Andrea Stoltefuß, Ursula Vehling-Kaiser, Michael Koenigsmann, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Thomas Illmer, Rudolf Schlag, Steffen Dörfel, Tobias Gaska, Michael Kiehl, Sigrun Müller-Hagen, Enno Moorahrend, Hartmut Linde, Anke Schlenska-Lange, Julia von Tresckow, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Anna Maria Fink
Long-term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long-term data collected within the GCLLSG registry. Altogether, 417 CLL patients who received first-line treatment with FCR were analyzed, of which 293 (70.3%) were treated outside of clinical trials. The median observation time from first-line was 95.8 (interquartile range 58.7-126.8) months. Focusing on data of 194 (46...
May 1, 2024: European Journal of Haematology
https://read.qxmd.com/read/38693052/impact-of-prior-treatment-on-selinexor-bortezomib-dexamethasone-outcomes-in-patients-with-relapsed-refractory-multiple-myeloma-extended-follow-up-subgroup-analysis-of-the-boston-trial
#18
JOURNAL ARTICLE
Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella Mesa, Michele Cavo, Meletios Dimopoulos, Martina Bianco, Giovanni Marino Merlo, Charles la Porte, Paul G Richardson, Philippe Moreau
OBJECTIVES: To analyze the impact of prior therapies on outcomes with selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in 402 patients with relapsed/refractory multiple myeloma (RRMM) in the phase 3 BOSTON trial. METHODS: Post hoc analysis of progression-free survival (PFS), overall survival (OS), and safety for lenalidomide-refractory, proteasome inhibitor (PI)-naïve, bortezomib-naïve, and one prior line of therapy (1LOT) patient subgroups...
May 1, 2024: European Journal of Haematology
https://read.qxmd.com/read/38665060/patients-with-aggressive-b-cell-lymphoma-receiving-car-t-cell-therapy-have-a-low-rate-of-severe-infections-despite-lack-of-universal-antibacterial-and-antifungal-prophylaxis
#19
JOURNAL ARTICLE
B Pernas, G Iacoboni, I Los-Arcos, C Carpio, E Márquez-Algaba, M A Sanchez-Salinas, A Albasanz, J Esperalba, B Viñado, I Ruiz Camps, P Barba
OBJECTIVES: Our aim was to describe the frequency and severity of infectious complications after chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL). METHODS: We retrospectively reviewed clinical records of LBCL patients treated with CD19-targeted CAR T-cell therapy from July/2018 to December/2021 at our institution, and identified all infectious episodes from CAR T-cell infusion until disease progression, death or last follow-up...
April 26, 2024: European Journal of Haematology
https://read.qxmd.com/read/38661269/front-line-and-second-line-treatment-for-mantle-cell-lymphoma-in-clinical-practice-a-multicenter-retrospective-analysis
#20
JOURNAL ARTICLE
Minna Harmanen, Marc Sorigue, Madiha Khan, Roosa Prusila, Tuula Klaavuniemi, Esa Kari, Esa Jantunen, Kaisa Sunela, Aino Rajamäki, Erika Alanne, Hanne Kuitunen, Arja Jukkola, Juan-Manuel Sancho, Outi Kuittinen, Aino Rönkä
BACKGROUND: There are few reports of clinical practice treatment patterns and efficacy in mantle cell lymphoma (MCL). MATERIALS AND METHODS: We retrospectively studied a large, multicenter, cohort of patients with MCL diagnosed between 2000 and 2020 in eight institutions. RESULTS: 536 patients were registered (73% male, median of 70 years). Front-line treatment was based on high-dose cytarabine, bendamustine, and anthracyclines in 42%, 12%, and 15%, respectively...
April 25, 2024: European Journal of Haematology
journal
journal
29503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.